Immunodiagnostic Systems Hldgs PLC AGM Statement (2126M)
July 27 2017 - 2:00AM
UK Regulatory
TIDMIDH
RNS Number : 2126M
Immunodiagnostic Systems Hldgs PLC
27 July 2017
AGM Statement
Immunodiagnostic Systems Holdings PLC
27 July 2017
Immunodiagnostic Systems Holdings plc
AGM Statement
Immunodiagnostic Systems Holdings PLC ("IDS" or "the Group"), a
specialist producer of manual and automated diagnostic testing kits
and instruments for the clinical market, will today hold its Annual
General Meeting at 2pm at its registered office at 10 Didcot Way,
Boldon Business Park, Boldon, Tyne & Wear, NE35 9PD.
At the meeting the Chairman, Dr. Burkhard Wittek, will make the
following statement to shareholders.
"Unaudited group revenues for Q1 FY18 are GBP9.7m, 2% higher
than the same period last year. On a like for like basis ("LFL"),
that is at constant exchange rate and constant scope, Group
revenues declined by 8%.
Revenue Performance in Q1 2018
The table below summarizes the unaudited revenue performance of
the core segments of our business:
Revenue LFL Growth
------------------------- --------- --------------------
Q1 FY18 Q1 FY18 FY17 v
v Q1 FY17 FY16
------------------------- --------- ----------- -------
Group GBP9.7m -8% -8%
------------------------- --------- ----------- -------
Automated business(1) GBP5.9m 7% 3%
------------------------- --------- ----------- -------
Automated 25-OH
Vitamin D GBP1.8m -3% -17%
------------------------- --------- ----------- -------
Specialty automated
business GBP3.7m 10% 16%
------------------------- --------- ----------- -------
Manual business GBP3.2m -6% -11%
------------------------- --------- ----------- -------
Licensing and
technology business GBP0.5m -65% -30%
------------------------- --------- ----------- -------
(1) the balance of the automated business not analyzed relates
to sales of instruments and support services.
We have been able to improve our rate of growth (versus that
seen in FY17), or slow our rate of decline, in all key areas of the
business with the exception of two:
-- LFL growth in our specialty automated business (i.e. all CLIA
assays excluding 25-OH Vitamin D) slowed to 10%. This is because Q1
FY17 revenues were abnormally high due to a significant one-off
sale to a new distributor. For the full year we still target
revenue growth on a LFL basis of approximately 15% for this
segment.
-- The decline in the licensing and technology business accelerated to -65%. This reflects the discontinuation of the business with one large customer which provided us with antibody royalty income. In Q1 FY18 the revenues with this customer accounted for 1% (Q1 FY17: 8%) of group revenues. Therefore the eventual total loss of these revenues will not materially drag down Group run rate revenues moving forward anymore.
Other KPIs
I would like to highlight the KPIs we are monitoring in our
automated business:
-- The average number of assays run on our installed base of
iSYS analyzers: This KPI increased to 4.3 (Q1 FY17: 3.9) reflecting
the ability of our sales organization for upselling.
-- Gross placements of analyzers in markets with direct sales
organization: This KPI stood at 12 (Q1 FY17: 8) during the quarter.
Net placements, after returns, stood at 8 (Q1 FY17: 5).
-- New product launches: no new CLIA product was launched in Q1
FY18 (Q1 FY17: 1). We still target four product launches with CE
mark in the current FY.
Closing cash and cash equivalents were GBP31.5m as at 30 June
2017 (31 March 2017: GBP31.5m).
At 30 June 2017 the Group employed 278 people on a full time
employment basis (31 March 2017: 275 persons).
Overall these results show that the efforts the Executives and
the team at IDS are undertaking put the company on a path to
strengthen our position in our markets and to lay the foundations
for future growth. I would like to thank them all for their
continuous efforts and would also like to thank our shareholders
for their continued loyalty and support of IDS. "
For further information:
Immunodiagnostic Systems Holdings plc Tel : +44 (0)191 5190660
Regis Duval, Chief Executive Officer
Paul Martin, Group Finance Director
Peel Hunt LLP Tel : +44 (0)207 418 8900
James Steel
Oliver Jackson
This information is provided by RNS
The company news service from the London Stock Exchange
END
AGMSEIFMMFWSELW
(END) Dow Jones Newswires
July 27, 2017 02:00 ET (06:00 GMT)
Immunodiagnostic Systems (LSE:IDH)
Historical Stock Chart
From Jun 2024 to Jul 2024
Immunodiagnostic Systems (LSE:IDH)
Historical Stock Chart
From Jul 2023 to Jul 2024